Top

Journal of Endocrinological Investigation

Published in:

01-10-2016 | Short Review

Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)

Authors: L. Bartalena, L. Chiovato, P. Vitti

Published in: Journal of Endocrinological Investigation | Issue 10/2016

Abstract

Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

Brent GA (2008) Graves’ disease. N Engl J Med 358:2594–2605PubMedCrossRef

Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734PubMedCrossRef

Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700PubMedCrossRef

Hammerstad SS, Tomer Y (2015) Epidemiology and genetic factors in Graves’ disease and Graves’ ophthalmopathy. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 21–37

Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294PubMedCrossRef

Rivkees SA (2016) Controversies in the management of Graves’ disease in children. J Endocrinol Invest. doi:10.1007/s40618-016-0477-x

Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 37:1041–1048CrossRef

Burch HB, Cooper DS (2015) Management of Graves disease. A review. JAMA 314:2544–2554PubMedCrossRef

Cooper DS (2005) Antithyroid drugs. N Engl J Med 352:905–917PubMedCrossRef

10.

Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O (2008) TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75PubMedCrossRef

11.

Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Invest 38:809–815PubMedCrossRef

12.

Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 97:4549–4558PubMedCrossRef

13.

Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 84:115–120CrossRef

14.

Glinoer D, Hesch D, Lagasse R, Laurberg P (1987) The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh) 285(suppl):3–23

15.

Solomon B, Glinoer D, Lagasse R, Wartofsky L (1990) Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 70:1518–1524PubMedCrossRef

16.

Wartofsky L, Glinoer D, Lagasse R, Solomon B (1991) Differences and similarities in the diagnosis and treatment of diffuse goiter in Europe, Japan and the United States. Thyroid 1:129–135PubMedCrossRef

17.

Emiliano AB, Governale L, Parks M, Cooper DS (2010) Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 95:2227–2233PubMedPubMedCentralCrossRef

18.

Sidibé EH (2007) Thyréopathies en Afrique subsaharienne (French). Cahiers Santé 17:33–39

19.

Ahmed ME, El Wasila AA, Sanhouri M, Yagi K (1993) Surgical management of toxic goiter in Khartoum. Trop Geogr Med 45:124–125PubMed

20.

Laurberg P, Cooper DS (2015) Antithyroid drug therapy in patients with Graves’ disease. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 65–82

21.

Abraham P, Avenell A, Park CM, Watson WA, Bevan JS (2005) A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 153:489–498PubMedCrossRef

22.

Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646CrossRef

23.

Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM (1994) Treatment of Graves’ disease with block-and-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 87:337–341PubMed

24.

Elbers L, Mourits M, Wiersinga W (2011) Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 21:279–283PubMedCrossRef

25.

Azizi F, Ataie L, Hedayati M, Mehrabi Y, Shekholeslami F (2005) Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152:695–701PubMedCrossRef

26.

Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M (2008) Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866–872PubMedCrossRef

27.

Laurberg P, Berman BC, Andersen S, Bulow Pedersen I (2011) Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid 21:951–956PubMedCrossRef

28.

Barbesino G, Tomer Y (2013) Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98:2247–2255PubMedPubMedCentralCrossRef

29.

Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375PubMedCrossRef

30.

Piantanida E, Lai A, Sassi L, Gallo D, Spreafico E, Tanda ML, Bartalena L (2015) Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res 47:767–772PubMedCrossRef

31.

Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S (2002) Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 147:583–589PubMedCrossRef

32.

Wang PW, Chen IY, Juo SH, Hsi E, Cy Hsieh (2012) Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J 1:251–258PubMedPubMedCentral

33.

Mohlin E, Filipsson Nystrom H, Eliasson M (2014) Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. Eur J Endocrinol 170:419–427PubMedCrossRef

34.

Glinoer D, de Nayer P, Bex M, The Belgian Collaborative Study Group on Graves’ disease (2001) Effects of L-thyroxine administration, TSH receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483PubMedCrossRef

35.

Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR (2002) Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest 25:152–157PubMedCrossRef

36.

Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Agabiti Rosei E, Chiovato L (2008) The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93:3985–3988PubMedCrossRef

37.

Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. doi:10.1210/jc.2015-3644 PubMed

38.

Watanabe N, Narimatsu H, Yoshimura Noh J, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito Ku, Ko Ito (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 97:E49–E53PubMedCrossRef

39.

Yang J, Zhu Y-J, Zhong J-J, Zhang J, Weng W-W, Liu Z-F, Xu Q, Dong M-J (2016) Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 26:627–633PubMedCrossRef

40.

Nakamura H, Maiyauchi A, Miyawaki N, Imagawa J (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 98:4776–4783PubMedCrossRef

41.

Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A (2009) Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than 15 mg daily. Thyroid 19:559–563PubMedCrossRef

42.

Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K (2014) Characteristics of agranulocytosis as an adverse effects of antithyroid drugs in the second or later course of treatment. Thyroid 24:796–801PubMedCrossRef

43.

Robinson J, Richardson M, Hickey J, James A, Pearce SH, Ball SG, Quinton R, Morris M, Miller M, Perros P (2014) Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J 3:245–251PubMedPubMedCentral

44.

Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH (2014) Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 78:619–629PubMedPubMedCentralCrossRef

45.

Yang J, Li LF, Xu Q, Zhang J, Weng W-W, Zhu YJ, Dong MJ (2015) Analysis of 90 cases of antithyroid drug-induced severe hepatoxicity over 13 years in China. Thyroid 25:278–283PubMedCrossRef

46.

Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN (2009) The role of propylthiouracil in the management of Graves’ disease in the adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673–674PubMedCrossRef

47.

Ross DS (2011) Radioiodine therapy for hyperthyroidism. N Engl J Med 364:542–550PubMedCrossRef

48.

Vaidya B, Williams GR, Abraham P, Pearce SHS (2008) Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf) 68:814–820CrossRef

49.

Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E (2010) Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 95:201–208PubMedCrossRef

50.

Martin NM, Patel M, Nijher GMK, Misra S, Murphy E, Meran K (2012) Adjuvant lithium therapy improves the efficacy of radioactive iodine treatment in Graves’ and toxic nodular disease. Clin Endocrinol (Oxf) 77:621–627CrossRef

51.

Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700–3707PubMedCrossRef

52.

Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–78PubMedCrossRef

53.

Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NC (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470PubMedCrossRef

54.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, On behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26PubMedPubMedCentralCrossRef

55.

Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333–1337PubMedCrossRef

56.

Shiber S, Stiebel-Kakish H, Shimon I, Grossman A, Robenshtok E (2014) Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid 24:1515–1523PubMedCrossRef

57.

Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P (1998) Mortality after treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338:712–718PubMedCrossRef

58.

Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J (2007) Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 92:2190–2196PubMedCrossRef

59.

La Cour JL, Jensen LT, Vej-Hansen A, Nygaard B (2015) Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol 172:771–778PubMedCrossRef

60.

Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, Doi SA (2012) Cancer risk after medical exposure to radioactive iodine in benign thyroid disease: a meta-analysis. Endocr Relat Cancer 19:645–655PubMedCrossRef

61.

Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, Auvinen A (2015) Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab 100:3710–3717PubMedCrossRef

62.

Boelaert K, Miasonneuve P, Torlinska B, Franklyn JA (2013) Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98:1869–1882PubMedCrossRef

63.

Canale D, Ceccarelli C, Cagliaresi C, Moscatelli A, Gavioli S, Santini P, Elisei R, Vitti P (2015) Effects of radioiodine treatment for differentiated thyroid cancer on testis function. Clin Endocrinol (Oxf) 82:295–299CrossRef

64.

Ceccarelli C, Canale D, Battisti P, Cagliaresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P (2006) Testicular function after ¹³¹I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 65:446–452CrossRef

65.

Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E (2013) What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol 20:660–667PubMedCrossRef

66.

Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS (2013) Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98:3671–3677PubMedPubMedCentralCrossRef

67.

Guo Z, Yu P, Liu Z, Si Y, Jin M (2013) Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ disease: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 79:739–746

68.

Grodski S, Stalberg P, Robinson BG, Delbridge LW (2007) Surgery versus radioiodine as definitive management for Graves’ disease: the role of patient preference. Thyroid 17:157–160PubMedCrossRef

69.

Ting HH, Brito JP, Montori VM (2014) Shared decision making. Science and action. Circ Cardiovasc Qual Outcomes 7:323–327PubMedCrossRef

70.

Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Singh Ospina N, Maraka S, Dean DS, Castro RM, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM (2015) Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves’ disease. Thyroid 25:1191–1198PubMedCrossRef

71.

Bartalena L (2011) The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592–599PubMedCrossRef

72.

Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1989) Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121(suppl 2):185–189

73.

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285PubMedCrossRef

74.

Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest 38:481–487PubMedPubMedCentralCrossRef

75.

Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1658PubMedCrossRef

76.

Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M (2013) Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44–E48CrossRef

77.

Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campenni A, Baldari S, Trimarchi F, Vermiglio F (2014) Radioiodine ablation of post-surgical remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves’ orbitopathy (GO): a prospective, randomized, single blind clinical trial. J Clin Endocrinol Metab 99:1783–1789PubMedCrossRef

78.

Stagnaro-Green A (2015) Graves’ disease and pregnancy. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 167–178

79.

De Groot L, Abalovich M, Alexander EA, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S (2012) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:2543–2565PubMedCrossRef

80.

Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W (2011) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21:1081–1125PubMedPubMedCentralCrossRef

81.

Fould N, Walpole I, Elmslie F, Mansour S (2005) Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 132A:130–135CrossRef

82.

Bowman P, Osborne NJ, Sturley R, Vaidya B (2012) Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. Q J Med 105:189–193CrossRef

83.

Cooper DS, Rivkees SA (2009) Putting PTU in perspective. J Clin Endocrinol Metab 94:1881–1882PubMedCrossRef

84.

Linding Andersen S, Olsen J, Wu CS, Laurberg P (2013) Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98:4373–4381CrossRef

85.

Linding Andersen S, Olsen J, Wu CS, Laurberg P (2014) Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 24:1533–1540CrossRef

86.

Gianetti E, Russo L, Orlandi F, Chiovato L, Giusti M, Benvenga S, Moleti M, Vermiglio F, Macchia PE, Vitale M, Regalbuto C, Centanni M, Martino E, Vitti P, Tonacchera M (2015) Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest 38:977–985PubMedCrossRef

87.

Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA (2013) Prevalence of thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid 23:758–765PubMedPubMedCentralCrossRef

88.

Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Seiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Musaka K, Ito K (2012) Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396–2403PubMedCrossRef

89.

Laurberg P, Linding Andersen S (2015) Antithyroid drug use in pregnancy and birth defects: why some studies find clear associations, and some studies report none. Thyroid 25:1185–1190PubMedCrossRef

90.

Rivkees SA, Mattison DR (2009) Ending propylthiouracil-induced liver failure in children. N Engl J Med 360:1574–1575PubMedCrossRef

91.

Havgaard Kjaer R, Smedegard Hansen M, Hansen D (2015) Increasing incidence of juvenile thyrotoxicosis in Denmark. A nationwide study, 1998–2012. Horm Res Paediatr 84:102–107PubMedCrossRef

92.

Read CH Jr, Tansey MJ, Menda Y (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 89:4229–4233PubMedCrossRef

93.

Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA (2008) Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058–3065PubMedCrossRef

94.

Weetman AP (2014) Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol (Oxf) 80:629–632CrossRef

95.

Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695PubMedCrossRef

96.

Cossburn M, Pace AA, Jones J, Ali R, Ingram C, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573–579PubMedCrossRef

97.

Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard J-P (2000) Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 85:4254–4257PubMed

98.

Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP (2005) Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine 84:98–106PubMedCrossRef

99.

Tailor IK, Akil M, Rennie I, Ross RJ, Snowden JA (2012) Reconstitution Graves’ disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis. Q J Med 105:369–371CrossRef

100.

Sinha A, Abinun M, Gennery AR, Barge D, Slatter M, Cheetam T (2013) Graves’ immune reconstitution inflammatory syndrome in Childhood. Thyroid 23:1010–1014PubMedCrossRef

101.

Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89PubMedCrossRef

102.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, For the CARE-MS investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828PubMedCrossRef

Title: Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)
Authors: L. Bartalena
L. Chiovato
P. Vitti
Publication date: 01-10-2016
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 10/2016
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0505-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis

Effects of crocin and voluntary exercise, alone or combined, on heart VEGF-A and HOMA-IR of HFD/STZ induced type 2 diabetic rats

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Sensitivity of assays for TSH-receptor antibodies

Epigenetics: spotlight on type 2 diabetes and obesity

Plasma total oxidant and antioxidant status after oral glucose tolerance and mixed meal tests in patients with polycystic ovary syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials